We report a case series of two patients in the intensive care unit with massive pulmonary embolism and obstructive shock who had resolution of shock after repeated administration of alteplase. Case Summaries: Both patients were initially dosed 10 mg of alteplase followed by infusion of 90 mg over 2 hours, but remained in obstructive shock requiring significant inotropic and vasopressor support. Both patients were deemed poor candidates for embolectomy. The first patient received repeated doses reaching an accumulative dose of 200 mg alteplase over 15 hours. The second patient received an accumulative dose of 250 mg alteplase over 36 hours. Both patients had resolution of shock within 24 hours of repeated administration of alteplase, but also experienced significant drops in hemoglobin, which were supported with transfusions. They were transferred out of the intensive care unit after resolution of obstructive shock and hemorrhage. The first patient died one week after transfer from the intensive care unit due to invasive candidiasis and septic shock. The second patient was weaned from the ventilator and discharged home. Conclusion: Patients with obstructive shock secondary to massive pulmonary embolism despite a one-time dose of alteplase and poor candidacy for embolectomy may benefit from repeated doses of alteplase. Due to the short half-life, repeated administration of thrombolytic may be appropriate for younger patients without absolute contraindications to thrombolysis, but future studies are needed to identify the optimal patient population.
INTRODUCTION
Pulmonary embolism (PE) is associated with significant in-hospital morbidity and mortality. Massive PE, defined as sustained hypotension with systolic blood pressures less than 90 mmHg for at least 15 minutes or requiring inotropic support, without evidence of other etiologies for shock, has a poor prognosis with in-hospital mortality reported as high as 52% (1) . Guidelines from medical societies recommend thrombolysis for massive PE, but there is limited evidence to support the superiority of any particular dosing regimen (2) (3) (4) . The recommended dosing of thrombolytic agents, most commonly tissue plasminogen activator (tPA), is derived from dated clinical trials evaluating the use of tPA for patients with acute myocardial infarction (AMI) (5-7). To our knowledge, repeated administration of thrombolytics in the setting of
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Tanaffos 2018; 17 (2) : [127] [128] [129] [130] [131] massive PE, too unstable for surgical embolectomy, has only been reported in patients with cardiac arrest (8-10), but may be beneficial for patients with persistent obstructive shock. We report two patients with massive PE with complete resolution of shock after multiple repeated administration of tPA with high 24-hour cumulative doses of tPA in the absence of cardiac arrest.. The mortality of patients with obstructive shock secondary to PE is high, and treatment with thrombolytic agents to relieve the obstructive etiology is recommended (6, 11, 12) . The risk of bleeding with tPA is not insignificant, with reports of major bleeding ranging from 9.1 to 11.5% (1, 6, 17, 18) . Studies have shown that older patients may be further predisposed to bleeding complications (16, 17) , and perhaps as in our cases, younger patients without absolute contraindications to thrombolysis may have a more favorable risk-benefit ratio. In the PEITHO trial, in which patients with submassive PE were given tenecteplase, only 4.1% of patients under 75 years old experienced major bleeding, versus 11.1% of those older than 75 (17) . Older patients may also be predisposed to higher risk with extended thrombolysis, as demonstrated by Stangl et al, who found stronger fibrinolytic properties among patients older than 63-years-old who received double-bolus doses (16) . As a result, in younger patients who are in shock requiring high doses of inotropic and vasopressor medications, too unstable for surgical intervention, repeated doses of tPA may be considered. Both of our patients experienced significant bleeding that was quickly stabilized, but overall they benefited from the hemodynamic improvement as a result of repeated thrombolysis. The BTS recommends fibrinolytic therapy 'on clinical grounds alone if cardiac arrest is imminent' (3) -we suggest that perhaps in younger patients without absolute contraindication to thrombolysis, with severe, persistent obstructive shock despite thrombolysis with 100 mg of tPA, there may be a role for repeated lysis beyond standard dosing. Further research is needed to identify an appropriate subset of patients with massive PE in whom repeated dosing of fibrinolytic may pose greater benefit than risk and optimal dosing regimens.
CASE SUMMARIES

Case One
